UnknownNot Applicable

COmprehensive Remote Ischemic Conditioning in Myocardial Infarction

China200 participantsStarted 2017-08-01

Plain-language summary

The primary objective of the CORIC-MI trial is to evaluate whether comprehensive (per, post plus delayed) remote ischemic conditioning (CORIC) as an adjunctive therapy in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) can improve left ventricular function and remodeling at 30 days assessed by cardiac magnetic resonance imaging (CMR) for a minimum follow-up period of 12 months.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Suspected anterior STEMI: new ST-elevation \> 0.1 millivolt (mV) (≥ 0.2 mV in men or ≥ 0.15 mV in women in leads V2-V3) in \> two contiguous leads in V1-V6; new or presumed new left bundle branch block; * Symptom onset no more than 12 h before presentation and planned primary PCI; * Age 18 to 75 years; * Willingness and capability to provide informed consent. Exclusion Criteria: * Previous anterior myocardial infarction; * Previous coronary artery bypass graft (CABG); * Myocardial infarction or stroke within the previous 30 days; * Treatment with thrombolysis within the previous 30 days; * Cardiogenic shock; * Thrombolysis in myocardial infarction (TIMI) flow grade 2 or 3 at coronary angiography; * Coronary anatomy or mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation) warranting emergent surgery; * Inability to obtain TIMI flow grade ≥ 2; * Conditions precluding use of RIC (paresis of lower limb, known severe peripheral artery disease or evidence of lower limb ischemia, and etc.); * Life expectancy of less than 12 months due to non-cardiac disease such as known malignancy or other comorbid conditions; * Contraindications to CMR; * Treated with therapeutic hypothermia before admission; * Pregnancy and lactating women; * Participation in another interventional trial.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

left ventricular ejection fraction (LVEF) assessed by CMR

Timeframe: at 30 days after MI

Trial details

NCT IDNCT03233919

SponsorChina National Center for Cardiovascular Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2019-01-30

Contact for this trial

hongbing yan, MD

0086+010 88322281 bcc_ami@126.com

View on ClinicalTrials.gov More Myocardial Infarction, Anterior Wall trials